Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Lexeo Therapeutics, Inc. (LXEO) had Stock-Based Compensation of $9.42M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-20.28M |
|
-- |
|
-- |
|
$21.65M |
|
$-21.65M |
|
$1.36M |
|
$-20.28M |
|
$-20.28M |
|
$-20.28M |
|
$-20.28M |
|
$-20.28M |
|
$-20.28M |
|
$-21.65M |
|
$-21.52M |
|
60.98M |
|
60.98M |
|
$-0.33 |
|
$-0.33 |
|
| Balance Sheet Financials | |
$127.79M |
|
$1.23M |
|
$16.05M |
|
$143.84M |
|
$17.27M |
|
$0.45M |
|
$5.74M |
|
$23.01M |
|
$120.83M |
|
$120.83M |
|
$120.83M |
|
54.93M |
|
| Cash Flow Statement Financials | |
$-78.48M |
|
$11.44M |
|
$73.02M |
|
$38.27M |
|
$44.24M |
|
$5.98M |
|
|
Stock-Based Compensation |
$9.42M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
7.40 |
|
-- |
|
-- |
|
0.00 |
|
0.01 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-78.88M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-16.79% |
|
-16.79% |
|
-14.10% |
|
-16.72% |
|
$2.20 |
|
$-1.29 |
|
$-1.29 |
|